Clinical Trials Logo

Metastatic Bone Tumor clinical trials

View clinical trials related to Metastatic Bone Tumor.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05427825 Recruiting - Clinical trials for Metastatic Bone Tumor

ERAS Anesthetic Care for Metastatic Spine Cancer Resection

Start date: July 2022
Phase: N/A
Study type: Interventional

Spinal metastases account for 60% of all malignant bone metastases and represent a medically important treatment goal. For patients with malignant tumors diagnosed at this stage, performing En bloc spondylectomy with wide margin of resection facilitate the improvement in quality of life including ambulatory ability, daily activities independence and attenuation of bone pain. However, En bloc spondylectomy is a major operation with long operation time and frequent hemodynamic instability during the operation. Therefore, the anesthetic care plays an important role and an enhanced recovery after surgery (ERAS) is the goal. For the ERAS anesthesia protocol for En bloc spondylectomy, we propose two major components to achieve this goal: (1) an encephalographic spectrum guided multimodal anesthesia combined with ultrasound-guided nerve block and (2) the advanced machine-learning algorithm index, namely the hypotension predictive index (HPI) guided hemodynamic protocol.

NCT ID: NCT05115331 Recruiting - Clinical trials for Metastatic Bone Tumor

Palliative UNConventional Hypofractionation Trial for Metastatic Bone Disease

1-2 PUNCH
Start date: November 24, 2021
Phase: Phase 3
Study type: Interventional

This is a randomized Phase III study evaluating the efficacy of hypofractionated and dose-escalated palliative radiation therapy in metastatic bone disease (MBD). Patients will be randomized 1:1 to the conventional (8 Gy in a single fraction) and experimental (16 Gy in 2 fractions) groups with baseline and subsequent assessment of both pain and quality of life metrics.

NCT ID: NCT05058014 Recruiting - Clinical trials for Metastatic Bone Tumor

Skeletal Metastasis Registry

Start date: August 16, 2018
Phase:
Study type: Observational [Patient Registry]

This is a prospective, observational study designed to contribute data from patients with symptomatic metastatic bone disease treated at Sibley Memorial Hospital and Johns Hopkins Medicine to an international registry hosted by the Swedish Regional Cancer Centrum in Stockholm, Sweden. This protocol supports a worldwide effort to collect and store information from patients treated for symptomatic bone metastases within the International Skeletal Metastasis Registry (ISMR)

NCT ID: NCT04634227 Recruiting - Sarcoma Clinical Trials

Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)

Start date: November 24, 2020
Phase: Early Phase 1
Study type: Interventional

This study will enroll patients who have a diagnosis of locally advanced, unresectable or metastatic soft tissue or bone sarcoma (except gastrointestinal stromal tumors and Kaposi's sarcoma) from any site.